MABCALIN Trademark

Trademark Overview


On Monday, December 19, 2022, a trademark application was filed for MABCALIN with the United States Patent and Trademark Office. The USPTO has given the MABCALIN trademark a serial number of 79361821. The federal status of this trademark filing is REGISTERED as of Tuesday, July 30, 2024. This trademark is owned by Pieris Pharmaceuticals GmbH. The MABCALIN trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical, veterinary and sanitary preparations, namely, artificial polypeptides and proteins and nucleic acids produced through genetic coding for the treatment or prevention of various types of cancers and autoimmune diseases; diagnostic reagents for medical or veterinary use, in particular for the diagnosis of various types of cancers and autoimmune diseases

Chemical preparations for industrial and scientific purposes; polypeptides and proteins produced by genetic engineering and nucleic acids produced through genetic coding for use in scientific research; diagnostic preparations, other than for medical or veterinary purposes

Scientific and industrial research, in particular in the biochemical, diagnostic or pharmaceutical fields; laboratory research services relating to biochemical and pharmaceuticals
mabcalin

General Information


Serial Number79361821
Word MarkMABCALIN
Filing DateMonday, December 19, 2022
Status700 - REGISTERED
Status DateTuesday, July 30, 2024
Registration Number7459076
Registration DateTuesday, July 30, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 14, 2024

Trademark Statements


Goods and ServicesPharmaceutical, veterinary and sanitary preparations, namely, artificial polypeptides and proteins and nucleic acids produced through genetic coding for the treatment or prevention of various types of cancers and autoimmune diseases; diagnostic reagents for medical or veterinary use, in particular for the diagnosis of various types of cancers and autoimmune diseases
Goods and ServicesChemical preparations for industrial and scientific purposes; polypeptides and proteins produced by genetic engineering and nucleic acids produced through genetic coding for use in scientific research; diagnostic preparations, other than for medical or veterinary purposes
Translation of Words in MarkThe wording MABCALIN has no meaning in a foreign language.
Goods and ServicesScientific and industrial research, in particular in the biochemical, diagnostic or pharmaceutical fields; laboratory research services relating to biochemical and pharmaceuticals

Classification Information


International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateMonday, February 6, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 6, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, February 6, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePieris Pharmaceuticals GmbH
Party Type30 - Original Registrant
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Party NamePieris Pharmaceuticals GmbH
Party Type20 - Owner at Publication
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Party NamePieris Pharmaceuticals GmbH
Party Type10 - Original Applicant
Legal Entity Type27 - NOT AVAILABLE
AddressDE

Trademark Events


Event DateEvent Description
Friday, February 3, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, February 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, February 10, 2023APPLICATION FILING RECEIPT MAILED
Wednesday, September 20, 2023ASSIGNED TO EXAMINER
Saturday, September 30, 2023NON-FINAL ACTION WRITTEN
Sunday, October 1, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, October 16, 2023REFUSAL PROCESSED BY MPU
Monday, October 16, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, November 7, 2023REFUSAL PROCESSED BY IB
Monday, April 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 8, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 8, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 14, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, July 12, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, May 14, 2024PUBLISHED FOR OPPOSITION
Friday, July 12, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, July 30, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Saturday, August 3, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, July 30, 2024REGISTERED-PRINCIPAL REGISTER
Wednesday, October 30, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, January 22, 2025FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, January 22, 2025FINAL DISPOSITION PROCESSED
Saturday, February 8, 2025FINAL DECISION TRANSACTION PROCESSED BY IB